[{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"1e4b972b-a78c-437b-a2e3-d4f2e74d347d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03952598","created_at":"2021-01-18T19:27:16.826Z","updated_at":"2025-02-25T13:39:51.583Z","phase":"Phase 2","brief_title":"Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy","source_id_and_acronym":"NCT03952598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/16/2019","start_date":" 10/16/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"7f66ca0f-1441-4209-9937-3fd50a8da5b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04242849","created_at":"2021-01-18T20:37:36.734Z","updated_at":"2025-02-25T13:40:03.346Z","phase":"","brief_title":"IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up","source_id_and_acronym":"NCT04242849","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 354","initiation":"Initiation: 05/23/2016","start_date":" 05/23/2016","primary_txt":" Primary completion: 12/27/2019","primary_completion_date":" 12/27/2019","study_txt":" Completion: 01/16/2020","study_completion_date":" 01/16/2020","last_update_posted":"2025-02-21"},{"id":"22e86fd8-4f8f-4456-992c-88f257edf9a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05345002","created_at":"2022-04-25T21:58:14.873Z","updated_at":"2025-02-25T14:41:19.773Z","phase":"Phase 2","brief_title":"All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma","source_id_and_acronym":"NCT05345002","lead_sponsor":"Stephen Bagley, MD, MSCE","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-14"},{"id":"6f7bf383-609e-4543-baf3-bf987cf68486","acronym":"","url":"https://clinicaltrials.gov/study/NCT03728335","created_at":"2023-11-24T19:04:58.043Z","updated_at":"2025-02-25T14:40:02.257Z","phase":"Phase 2","brief_title":"Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation","source_id_and_acronym":"NCT03728335","lead_sponsor":"City of Hope Medical Center","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 01/11/2027","primary_completion_date":" 01/11/2027","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-02-14"},{"id":"d6b5f034-4f23-41ab-9424-0eeb245d22d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04203316","created_at":"2021-01-18T20:28:43.981Z","updated_at":"2025-02-25T15:11:26.261Z","phase":"Phase 2","brief_title":"Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation","source_id_and_acronym":"NCT04203316","lead_sponsor":"Children's Oncology Group","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/14/2023","start_date":" 08/14/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-02-13"},{"id":"35a86a04-d158-4bfb-8750-bfb724605cdd","acronym":"P30CA016672","url":"https://clinicaltrials.gov/study/NCT03383575","created_at":"2021-01-18T16:41:48.451Z","updated_at":"2025-02-25T14:37:54.258Z","phase":"Phase 2","brief_title":"Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome","source_id_and_acronym":"NCT03383575 - P30CA016672","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IDH2 • RUNX1 • ASXL1","pipe":" | ","alterations":" IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation","tags":["TP53 • IDH2 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-10"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"4d0aa8dd-1906-440f-bdc4-7b7bd07db44b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076513","created_at":"2021-10-13T16:58:18.037Z","updated_at":"2025-02-25T13:12:47.827Z","phase":"Phase 1","brief_title":"Trial of Niraparib in Participants with Newly-diagnosed Glioblastoma and Recurrent Glioma","source_id_and_acronym":"NCT05076513","lead_sponsor":"Nader Sanai","biomarkers":" IDH1 • IDH2 • ATRX","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-23"},{"id":"a154a323-d6ef-4152-926e-c4ab1ae75b5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05756777","created_at":"2023-03-06T15:01:58.629Z","updated_at":"2025-02-25T15:36:05.770Z","phase":"Phase 1","brief_title":"A Study of Gilteritinib in Combination with Ivosidenib or Enasidenib in People with Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05756777","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • FLT3 mutation","tags":["FLT3 • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • Tibsovo (ivosidenib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-11-12"},{"id":"12c4bdec-2faf-43d1-a25f-e666a7565100","acronym":"NCI-2022-02837","url":"https://clinicaltrials.gov/study/NCT05282459","created_at":"2022-03-16T15:54:13.299Z","updated_at":"2025-02-25T14:16:45.662Z","phase":"Phase 1/2","brief_title":"Enasidenib in MDS \u0026Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation","source_id_and_acronym":"NCT05282459 - NCI-2022-02837","lead_sponsor":"Stanford University","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-09-26"},{"id":"bdecc9b3-c8fa-4ac1-b2d7-05e45884f6a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04522895","created_at":"2021-01-18T21:39:54.008Z","updated_at":"2025-02-25T14:29:32.125Z","phase":"Phase 2","brief_title":"IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT","source_id_and_acronym":"NCT04522895","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/24/2024","primary_completion_date":" 07/24/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2024-09-19"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • Idhifa (enasidenib) • idarubicin hydrochloride • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"711f8265-575f-4a14-bb60-be585609d334","acronym":"","url":"https://clinicaltrials.gov/study/NCT05024994","created_at":"2021-08-27T12:53:02.872Z","updated_at":"2025-02-25T13:35:55.158Z","phase":"Phase 2","brief_title":"A Study of E7820 in People With Bone Marrow (Myeloid) Cancers","source_id_and_acronym":"NCT05024994","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation","tags":["FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7820"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/13/2021","start_date":" 08/13/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-07-03"},{"id":"6e3accdd-5a43-478f-a02d-784bf9cd8ce5","acronym":"NCI-2018-00876","url":"https://clinicaltrials.gov/study/NCT03528642","created_at":"2021-01-18T17:22:22.349Z","updated_at":"2024-07-02T16:34:37.431Z","phase":"Phase 1","brief_title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","source_id_and_acronym":"NCT03528642 - NCI-2018-00876","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"450196e9-e0ad-47bf-a736-4b3fdabb7b6e","acronym":"NCI-2019-03057","url":"https://clinicaltrials.gov/study/NCT03953898","created_at":"2021-01-18T19:27:50.729Z","updated_at":"2024-07-02T16:34:37.850Z","phase":"Phase 2","brief_title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","source_id_and_acronym":"NCT03953898 - NCI-2019-03057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"1b7433f8-fdf4-4ed8-b6bd-286988acbcd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521686","created_at":"2021-01-18T21:39:29.090Z","updated_at":"2024-07-02T16:34:37.926Z","phase":"Phase 1","brief_title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04521686","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"67ee693c-6b97-4b0f-b34b-6654a4861bbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603001","created_at":"2021-01-19T20:30:51.296Z","updated_at":"2024-07-02T16:34:58.765Z","phase":"Phase 1","brief_title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04603001","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/03/2023","primary_completion_date":" 07/03/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"ae31087b-9b60-4d29-a1c0-25dbec311809","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718767","created_at":"2021-01-18T18:13:28.980Z","updated_at":"2024-07-02T16:34:58.828Z","phase":"Phase 2","brief_title":"Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype","source_id_and_acronym":"NCT03718767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["TMB • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/27/2026","study_completion_date":" 02/27/2026","last_update_posted":"2024-06-05"},{"id":"ab92a282-919a-4023-ac7a-0869d1798034","acronym":"NCI-2021-00893","url":"https://clinicaltrials.gov/study/NCT04774393","created_at":"2021-03-01T14:52:29.975Z","updated_at":"2024-07-02T16:34:59.147Z","phase":"Phase 1/2","brief_title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04774393 - NCI-2021-00893","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-06-04"},{"id":"ca13f616-bab8-4eca-8a94-b55ce8f19f86","acronym":"PNOC017","url":"https://clinicaltrials.gov/study/NCT03749187","created_at":"2021-01-18T18:23:03.471Z","updated_at":"2024-07-02T16:35:02.572Z","phase":"Phase 1","brief_title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","source_id_and_acronym":"NCT03749187 - PNOC017","lead_sponsor":"University of California, San Francisco","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 07/30/2029","study_completion_date":" 07/30/2029","last_update_posted":"2024-05-20"},{"id":"8420d34e-5720-4abb-8b0f-9d930a4e3baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03212274","created_at":"2021-01-18T15:50:38.215Z","updated_at":"2024-07-02T16:35:02.706Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT03212274","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-17"},{"id":"8a546e53-8398-4bf1-9589-03660de842b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03878095","created_at":"2021-01-18T19:07:08.982Z","updated_at":"2024-07-02T16:35:02.694Z","phase":"Phase 2","brief_title":"Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors","source_id_and_acronym":"NCT03878095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Suspended","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"409da099-f4a0-4d19-8f1c-da9bf68bdd78","acronym":"DIAMOND-01","url":"https://clinicaltrials.gov/study/NCT03008187","created_at":"2021-05-17T08:53:01.393Z","updated_at":"2024-07-02T16:35:04.730Z","phase":"Phase 1/2","brief_title":"SEL24/MEN1703 in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03008187 - DIAMOND-01","lead_sponsor":"Menarini Group","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dapolsertib (MEN1703)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 04/13/2023","study_completion_date":" 04/13/2023","last_update_posted":"2024-05-09"}]